Patient characteristic based adaptive anti-tachy pacing programming

• US 7,873,414 B2
• Filed: 04/17/2007
• Issued: 01/18/2011
• Est. Priority Date: 04/17/2007
• Status: Active Grant

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Zhong, Qian, Wei, Xuan, Li, Dan, Dong, Yanting, Ni, Quan
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Stice; Paula J
• Application Number:
  US11/736,286
• Publication Number:
  US 20080262558A1
• Time in Patent Office: 1,372 Days
• Field of Search: 607 1- 45, 607/14, 600/643
• US Class Current: 607/14
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate

Abstract

A system including at least one implantable sensor circuit adapted to produce an electrical sensor signal related to one or more physiologic cardiovascular events of a subject, a therapy circuit configured to provide anti-tachycardia pacing (ATP) therapy, and a controller. The controller includes a tachyarrhythmia detection circuit and an efficacy circuit. The tachyarrhythmia detection circuit is configured to detect a tachyarrhythmia episode in the subject using the electrical sensor signal, and to determine whether the tachyarrhythmia episode is of a type that is treatable with ATP. The efficacy circuit is configured to estimate an efficacy of a currently configured ATP therapy for the subject, and the controller is configured to alter a delivery regimen of the currently configured ATP therapy when the estimated ATP therapy efficacy is deemed insufficient. Other systems and methods are described.

Claims

1. A system comprising:

a first device including;

at least one implantable sensor circuit configured to produce an electrical sensor signal related to one or more physiologic cardiovascular events of a subject;

a therapy circuit configured to provide anti-tachycardia pacing (ATP) therapy and

a controller, communicatively coupled to the sensor circuit and the therapy circuit, the controller including;

a tachyarrhythmia detection circuit configured to detect a tachyarrhythmia episode in the subject using the electrical sensor signal, and to determine whether the tachyarrhythmia episode is of a type that is treatable with ATP; and

an efficacy circuit configured to, before beginning delivery of a currently configured ATP therapy in response to the detected tachyarrhythmia episode, estimate a cumulative subject-specific currently-configured ATP therapy efficacy, and wherein the controller is configured to;

compare the cumulative subject-specific efficacy to a physiological condition specific efficacy threshold determined using a patient population; and

alter the delivery regimen of the ATP therapy when the cumulative subject-specific efficacy is less than the physiological condition-specific efficacy threshold.

2. The system of claim 1, comprising a second device including:

a communication circuit;

a memory configured to store data related to conversion of tachyarrhythmia by ATP therapy; and

a processor, communicatively coupled to the communication circuit and the memory, including an efficacy threshold circuit configured to;

receive an indication of a physiologic condition of the subject and the currently configured ATP therapy of the first device;

check the memory for data related to conversion of tachyarrhythmia by ATP therapy for the physiologic condition; and

determine the physiologic condition-specific efficacy threshold, and wherein the processor is configured to communicate the physiologic condition-specific efficacy using the communication circuit.

3. The system of claim 2, wherein the efficacy threshold circuit is configured to receive the indication of a physiologic condition of the subject via the communication circuit.

4. The system of claim 2, wherein the second device includes a user interface configured to be coupled to the processor, and wherein the efficacy threshold circuit is configured to receive the indication of a physiologic condition of the subject via the user interface.

5. The system of claim 2, wherein the second device includes a server communicatively coupled to a communication network.

6. The system of claim 5, wherein the first device includes:

a memory configured to store an indication of the physiologic condition of the subject; and

a communication circuit configured to communicate to a separate device information about the indication of the physiologic condition and the physiologic condition-specific efficacy threshold.

7. The system of claim 5, including a third device configured to communicate information between the first device and the second device.

8. The system of claim 2, wherein the second device includes a display configured to be coupled to the processor, and wherein the processor is configured to display at least one of an efficacy estimated using at least a portion of the data.

9. The system of claim 8, wherein the processor is configured to display an indication of an alternate ATP therapy and to initiate a change to the currently configured ATP therapy after an indication of a confirmation is received by the second device, wherein the second device is separate from the first device.

10. The system of claim 1, wherein the first device comprises:

a memory, communicatively coupled to the controller, to store an indication of tachyarrhythmia conversion for the currently configured ATP therapy for multiple previous tachyarrhythmia episodes of the subject; and

wherein the efficacy circuit is configured to estimate the cumulative subject-specific currently-configured ATP therapy efficacy using conversion success information about the multiple previous.

11. The system of claim 10, wherein the memory is configured to store the indication of tachyarrhythmia conversion for a number of previous tachyarrhythmia episodes, wherein the number of previous tachyarrhythmia episodes is specified according to a physiologic condition of the subject.

12. The system of claim 1, wherein the first device includes a memory, communicatively coupled to the controller, configured to store at least one parameter related to the currently configured ATP therapy, and wherein the controller is configured to change the parameter when the cumulative subject-specific currently-configured ATP therapy efficacy is deemed insufficient.

13. The system of claim 12, wherein the first device includes a communication circuit, communicatively coupled to the controller, configured to receive the parameter from a separate device.

14. The system of claim 1, wherein the first device includes a memory, communicatively coupled to the controller, configured to store a plurality of ATP therapy regimens, and wherein the controller is configured to change from the currently configured ATP therapy to a different ATP therapy regimen stored in the medical device when the cumulative subject-specific currently-configured ATP therapy efficacy is deemed insufficient.

15. The system of claim 1, wherein the first device includes a memory, communicatively coupled to the controller, configured to store a plurality of ATP therapy regimens, and wherein the controller is configured to re-prioritize the ATP therapy regimens when the cumulative subject-specific currently-configured ATP therapy efficacy is deemed insufficient.

16. The system of claim 1, wherein the controller is configured to cancel the currently configured ATP therapy when the estimated cumulative subject-specific currently-configured ATP therapy efficacy is deemed insufficient.

17. The system of claim 1, wherein the therapy circuit is configured to deliver high-energy shock therapy, and wherein the controller is configured to initiate high-energy shock therapy when the cumulative subject-specific currently-configured ATP therapy efficacy is deemed insufficient.

18. The system of claim 1, including:

a memory, coupled to the controller, configured to store at least one ATP therapy in correspondence with a tachyarrhythmia rate zone;

wherein the tachyarrhythmia detection circuit is configured to detect the tachyarrhythmia episode when a heart rate of the subject is within a specified tachyarrhythmia rate zone; and

wherein the controller is configured to alter, when the cumulative subject-specific currently-configured ATP therapy efficacy is deemed insufficient, a delivery regimen including altering an ATP therapy regimen corresponding to a tachyarrhythmia rate zone corresponding to the heart rate of the tachyarrhythmia.

19. The system of claim 1, comprising a second device including:

a communication circuit configured to receive an indication of a physiologic condition of the subject and the currently configured ATP therapy of the first device; and

an indicator circuit configured to provide an indication that an estimated currently configured ATP therapy efficacy for the subject is deemed insufficient.

20. The system of claim 19, wherein the indicator circuit includes a display to display the indication and to display a recommended change to the currently configured ATP therapy.

21. A method comprising:

detecting a tachyarrhythmia episode in a subject using a medical device, wherein the tachyarrhythmia episode is of a type treatable with anti-tachycardia pacing (ATP);

before beginning delivery of the currently configured ATP therapy in response to the detected tachyarrhythmia episode, estimating an efficacy for the subject of an ATP therapy currently configured in the medical device;

comparing the estimated efficacy to a physiological condition-specific threshold value, wherein the efficacy threshold value is statistically determined using a patient population; and

altering a delivery regimen of the currently configured ATP therapy when the estimated efficacy of the ATP therapy is deemed insufficient.

22. The method of claim 21, including:

determining a physiologic condition-specific efficacy threshold that is specific to a physiologic condition of the subject;

determining a cumulative subject-specific currently configured ATP therapy efficacy, wherein comparing the estimated efficacy to a specified efficacy threshold value includes comparing the cumulative subject-specific ATP therapy efficacy to the physiologic condition-specific efficacy threshold; and

altering the delivery regimen of the ATP therapy when the cumulative subject-specific ATP therapy efficacy is less than the physiologic condition-specific efficacy threshold.

23. The method of claim 22, wherein determining the physiologic condition-specific efficacy threshold includes:

recurrently checking for stored data related to efficacy of ATP therapy;

using at least some of the data to estimate a physiologic condition-specific currently configured ATP therapy efficacy; and

communicating information about the physiologic condition-specific currently configured ATP therapy efficacy.

24. The method of claim 23, including displaying at least one of an efficacy determined using at least some of the data and at least a portion of the data.

25. The method of claim 21, wherein the estimating the efficacy includes estimating the currently configured ATP therapy efficacy over multiple previous tachyarrhythmia episodes of the subject.

26. The method of claim 25, including using the physiologic condition of the subject for determining a specified number of previous tachyarrhythmia episodes for the estimating the efficacy.

27. The method of claim 21, wherein the altering the delivery regimen includes changing the currently configured ATP therapy.

28. The method of claim 27, wherein changing the currently configured ATP therapy includes downloading a different ATP therapy regimen from a remote external device to the medical device.

29. The method of claim 27, wherein changing the currently configured ATP therapy includes downloading a different ATP therapy regimen from a local external device to the medical device.

30. The method of claim 27, wherein changing the currently configured ATP therapy includes changing to a different ATP therapy regimen stored in the medical device.

31. The method of claim 27, wherein changing the currently configured ATP therapy includes re-prioritizing ATP regimens stored in the medical device.

32. The method of claim 27, wherein the changing the currently configured ATP therapy includes displaying an alternate ATP therapy on a separate second device and changing the currently configured ATP therapy after an indication of confirmation is received into the separate second device.

33. The method of claim 21, wherein the altering the therapy regimen includes canceling the currently configured ATP therapy.

34. The method of claim 21, including detecting a heart rate that is within a specified tachyarrhythmia rate zone, and wherein the altering a delivery regimen includes altering a delivery regimen of the currently configured ATP therapy corresponding to the specified tachyarrhythmia rate zone.

35. The method of claim 21, wherein the altering the therapy regimen includes generating an indication that an efficacy of the currently configured ATP therapy for the subject is less than a specified efficacy threshold.

36. The method of claim 35, including displaying a recommended change to the currently configured ATP therapy.

37. A system comprising:

means for detecting a tachyarrhythmia episode in a subject using a medical device, wherein the tachyarrhythmia episode is of a type treatable with anti-tachycardia pacing (ATP);

means for, before beginning delivery of the currently configured ATP therapy in response to the detected tachyarrhythmia episode, estimating an efficacy for the subject of an ATP therapy currently configured in the medical device;

means for comparing the estimated efficacy to a physiological condition-specific threshold value wherein the efficacy threshold value is statistically determined using a patient population; and

means for altering a delivery regimen of the currently configured ATP therapy when the estimated efficacy of the ATP therapy is deemed insufficient.